Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anita Lumeka Kabwende"'
Autor:
Teite Rebecca Hildebrandt, Saskia Dede Davi, Anita Lumeka Kabwende, Lilian Rene Endamne, Esther Mehmel, Maximilian Rakotonirinalalao, Ayodele Alabi, Rella Zoleko Manego, Peter G Kremsner, Bertrand Lell, Ayôla Akim Adegnika, Ghyslain Mombo-Ngoma, Johannes Mischlinger, Selidji Todagbe Agnandji, Michael Ramharter
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 18, Iss 5, p e0012109 (2024)
BackgroundMore than 20 million people are infected with L. loa, and around 40 million live in high or intermediate-risk areas in West- and Central Africa. Although loiasis is associated with significant morbidity and excess mortality, little is known
Externí odkaz:
https://doaj.org/article/ab1db3adb5ab479ca4f14a75238c2a6c
Autor:
Sabine Yerly, Saskia Borregaard, Benjamin Tsofa, Axel Finckh, Marylyn M. Addo, Laurent Kaiser, Christophe Combescure, Sarah Katharina Fehling, Martin P. Grobusch, Alen Jambrecina, Philip Bejon, Marie-Paule Kieny, Markus Eickmann, Selidji T Agnandji, Nadine Biedenkopf, Michael Ramharter, Patricia Njuguna, Alain Matthey, Domtila Kimani, Rahel Kasonta, Ansgar W. Lohse, Angela Huttner, Emmanuel B. Bache, Patricia E. Fast, Hans Stubbe, Rebekah Burrow, Vasee S. Moorthy, Verena Kraehling, Henry M. Staines, Stefan Schmiedel, Anne Nolting, Gürkan Kaya, A.A. Adegnika, Jessica S Brosnahan, Jay W. Hooper, Marguerite Massinga-Loembe, Thomas Strecker, Sanjeev Krishna, Stephan Becker, Christine Dahlke, José Francisco Fernandes, Sherif R. Zaki, Caroline Ogwang, Floriane Auderset, Benjamin Mordmüller, Peter Silvera, Madeleine E Zinser, Claire-Anne Siegrist, Ana Rita Gonçalves, Jules Alexandre Desmeules, Anita Lumeka Kabwende, Jonas Schmidt-Chanasit, Julie-Anne Dayer, Peter G. Kremsner, Bertrand Lell, Barbara Lemaître, Felix R. Stahl, Marcus Altfeld
Publikováno v:
New England journal of medicine, 374(17), 1647-1660. Massachussetts Medical Society
BACKGROUND: The replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa. METHODS: We p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b58960e1f9c2061a980829151175ea6
https://doi.org/10.1056/nejmoa1502924
https://doi.org/10.1056/nejmoa1502924
Autor:
Anita Lumeka Kabwende, Bache Emmanuel Bache, Martin P. Grobusch, Peter G. Kremsner, Agnandji Selidji Todagbe, Régis M Obiang, José Francisco Fernandes, Sanjeev Krishna
Publikováno v:
BMJ Global Health. 2:A13.1-A13
Background The rVSV∆G-ZEBOV-GP vaccine was safe and immunogenic in American, European and African adults. Few cases of transient, self-limiting arthritis have been reported in some adult participants in Geneva. We describe one-year safety of a sing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2543a2a43db9d0119e38c92e46f287c8
https://doi.org/10.1136/bmjgh-2016-000260.30
https://doi.org/10.1136/bmjgh-2016-000260.30
Autor:
Esther Oguk, Trudie Lang, Harry Owusu Boateng, Laurence Slutsker, Patricia Njuguna, Francis Martinson, Justice Sylverken, Saumu Ahmed, Nahya Salim, Christine Kerubo, Omari Abdul, Pedro Aide, Gerald Tegha, Innocent Valea, Kevin Marsh, Chimwemwe Chawinga, Preeti Vansadia, Ayola A. Adegnika, Ali Hamad, Irving F. Hoffman, Vincent Muturi-Kioi, Evans Kwara, Norbert Awino, Daniel Ansong, Halidou Tinto, Helder Bulo, Seth Owusu-Agyei, Chris Drakeley, Peter G. Kremsner, Stacey M. O. Gondi, Eusebio Macete, Edwin Liheluka, George Odongo, Owusu Boahen, Kwaku Poku Asante, Portia Kamthunzi, Sonia Machevo, Didier Leboulleux, Mary J. Hamel, Selidji T Agnandji, Samwel Gesase, Jane Kilembe, Hermann Sorgho, Lucas Otieno, Kayla F. Laserson, Marc Lievens, Rutendo Nkomo, Robert T. Guiguemdé, Betuel Sigaúque, Biebo Bihoun, Anangisye Malabeja, Jahit Sacarlal, David C. Kaslow, Daniel Chandramohan, David Schellenberg, Olivier Sombié, Bernhards Ogutu, Roma Chilengi, Ali Ali, Maxmillian Mpina, Amanda J. Leach, Thor G. Theander, John Lusingu, Jean-Bosco Ouédraogo, Anita Lumeka Kabwende, Anima Sarfo, David Dosoo, Benjamin Mordmüller, Pedro L. Alonso, Tisungane Mvalo, Ali Mtoro, Charity Maingi, Yolanda Guerra, John Bawa, Alex Agyekum, Mercy Tsidya, Christian Loucq, Simon Kariuki, Meredith McMorrow, Brian Greenwood, Berenger Kaboré, Barbara Gaelle Nfono Ondo Methogo, Didier Lapierre, Joe Cohen, Samuel Adjei, Johan Vekemans, Barbara Savarese, Marla Sillman, Gabriel Mwambingu, David Sambian, Afiya Radford, George Adjei, Philip Bejon, Walter Otieno, Saadou Issifou, Paul Mutani, Umberto D'Alessandro, Chris Odero, Allan Otieno, Béatrice Peggy Abossolo, Tsiri Agbenyega, Marcel Tanner, Ally Olotu, Lincoln Malle, Kingsley Osei-Kwakye, Tapiwa Tembo, Rose Minja, Salim Abdulla, W. Ripley Ballou, Bertrand Lell, Opokua Ofori-Anyinam, Terrell Carter, José Francisco Fernandes, Miguel Lanaspa, Coline Mahende, Theresa Rettig, Aurélie Olivier, Issa Guiraud, Jon Ben Woods, Nekoye Otsyula, Pauline Akoo, Erik Jongert, M.M. Lemnge, Victorine Owira, Kephas Otieno, Sozinho Acácio, John J. Aponte, Martina Oneko, Isaac Asante
BACKGROUND: The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beaf1d9dda3fe0877c22029a20ff4a88
